2001
DOI: 10.1038/89653
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Abstract: Certain chemokines act as natural antagonists of human immunodeficiency virus (HIV) by blocking key viral coreceptors, such as CCR5 and CXCR4, on the surface of susceptible cells. Elucidating the structural determinants of the receptor-binding and HIV-inhibitory functions of these chemokines is essential for the rational design of derivative molecules of therapeutic value. Here, we identify the structural determinants of CCR5 recognition and antiviral activity of the CC chemokine RANTES, showing that critical … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
15
0

Year Published

2004
2004
2014
2014

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 48 publications
(16 citation statements)
references
References 27 publications
1
15
0
Order By: Relevance
“…However, several small–medium size peptides and many large peptides and/or proteins are still unavailable by classical methods. One example is RANTES, a 68 amino acid chemokine (Figure 1) that has a high propensity to aggregate 2, 3…”
Section: Introductionmentioning
confidence: 99%
“…However, several small–medium size peptides and many large peptides and/or proteins are still unavailable by classical methods. One example is RANTES, a 68 amino acid chemokine (Figure 1) that has a high propensity to aggregate 2, 3…”
Section: Introductionmentioning
confidence: 99%
“…Similarly, several small CCR5 antagonists have been reported to block HIV-1 infection 100102 (Table 2). TAK-779, a non-peptide compound, binds to CCR5 primarily via polar interactions with Glu 283 and Tyr 37 , hydrophobic interactions with Phe 10 , Phe 112 , Phe 113 , Ile 198 and Trp 248 deeply buried in the TM regions, and a face-to-face aromatic stacking contact with Tyr 108 103,104 .…”
Section: Chemokine Receptor Inhibitorsmentioning
confidence: 99%
“…RANTES has also been shown to possess antiviral properties. Treatment with recombinant CCL5 or with synthetic peptides representing the N-terminal loop of CCL5 inhibited infection of human monocyte cultures by a CCR5-dependent human immunodeficiency virus strain [12]. Pretreatment with biologically inactive met-CCL5 also significantly inhibited infection of human epithelial cells with respiratory syncytial virus [13].…”
Section: Introductionmentioning
confidence: 94%